ProSomnus is the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide that is associated with comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many government-sponsored healthcare plans around the world, representing over 200 million covered lives.

The following ProSomnus process and family of products are protected by patents in the United States and elsewhere. This web page is provided to satisfy the virtual patent marking provisions of various jurisdictions, including but not limited to the virtual patent marking provisions of Section 16 of the America Invents Act. It is also intended to serve as notice under 35 U.S.C. § 287(a).

Other ProSomnus products not listed here may be protected by one or more patents in the United States and elsewhere.

U.S. Patents List

  • 9,808,327
  • 9,820,882
  • 9,949,868
  • 10,213,280
  • 10,603,207
  • 11,179,268
  • 11,207,207
  • 11,291,580
  • 11,607,183
  • 11,617,677
  • D932626
  • US 2021-0228320
  • US 2022-0019192
  • US 2022-0330888
  • US 2023-0218242
  • US 2023-0277367
  • 18/028,453
  • 18/387,227
  • 63/461,694
  • 63/461,697

Foreign Patents List

  • AU2014373973
  • EP 3 487 444 validated in France
  • EP 3 487 444 validated in Germany
  • EP 3 487 444 validated in United Kingdom
  • AU2020401372
  • CA3070555
  • CA3160796
  • CN2020800865096
  • EP14877266.8
  • EP20899290.9
  • EP21873562.9
  • JP2022-535827
  • KR10-2022-7023091

Ready, Set, SLEEP.

Join hundreds of thousands of people sleeping restfully with ProSomnus.

Applicant Form

Thank you for your interest in ProSomnus career opportunities. Please choose your department of interest:

Resume Upload

By submitting this form, you may be contacted by our staff to verify information.

Brian Dow

Chief Financial Officer

Brian Dow is the Chief Financial Officer for ProSomnus® Sleep Technologies. Prior to joining ProSomnus in March of 2023, Mr. Dow served as Chief Financial Officer of Agendia N.V., a $60 million molecular diagnostics company, Senior Vice President and Chief Financial Officer of Pulse Biosciences (NASDAQ: PLSE), a development stage medical device company, and Principal Accounting Officer for Pacific Biosciences (NASDAQ: PACB), a commercial stage developer, manufacturer and provider of next generation sequencing instruments. Mr. Dow started his career as a manager with Ernst & Young.

Mr. Dow holds a B.S. in Management from the Georgia Institute of Technology and is recognized as a licensed certified public accountant by the Washington State Board of Accountancy.

Cookies on

This site uses cookies to provide the best possible user experience. This includes features to measure performance, reliability, and overall site health. By continuing on to use the site, you agree to accept these cookies. 

Request Your Provider Portal Login Credentials

Please complete the form. A ProSomnus team member will reach out to you with your unique login credentials.

Request an Appointment